Every batch HPLC-assayed for ≥99.5% purity, specific rotation-confirmed for L-isomer identity, and tested for heavy metals, microbial limits, and residual solvents. Full USP/BP documentation with every shipment.
Assay ≥99.5% (free base) by HPLC. Specific rotation [α]D²⁰ = +26.9° to +27.9° confirms pure L-isomer. Absence of D-arginine and related amino acid impurities verified. USP/BP COA with each batch.
Bacterial fermentation (non-animal derived). Non-GMO certification available. Fermentation batch records provided. Free from TSE/BSE risk. Identity confirmed by IR spectroscopy and amino acid analysis.
Lead NMT 0.5 ppm; Arsenic NMT 0.5 ppm; Mercury NMT 0.1 ppm; Cadmium NMT 0.2 ppm. TPC NMT 10³ CFU/g; absence of Salmonella, E. coli, Staph. aureus per USP methods.
COA, MSDS, Certificate of Origin; USP/BP analytical certificates; FSSAI compliance; Halal and Kosher on request; full traceability to fermentation batch. Digital documentation before shipment.
L-Arginine is one of the most studied amino acids with clinical evidence spanning cardiovascular medicine, sports performance, wound healing, and immunology. Selecting the right salt form, dose, and application context is critical to product efficacy and safety.
Alkaline in solution. Highest arginine content per gram — 100% vs 82.7% for HCl salt. Preferred for capsules, tablets, and powder blends where solubility is less critical. Lower cost per gram of active arginine. Most clinical studies use free base. Standard for wound healing and clinical nutrition protocols.
Highly water-soluble, neutral-to-slightly acidic pH in solution. Preferred for beverages, ready-to-drink products, and effervescent tablets. Account for lower arginine content per gram when formulating: a 5g dose of arginine requires ~6g of arginine HCl. More stable in solution than free base at acidic pH.
L-Citrulline achieves higher plasma arginine levels than equivalent oral doses of L-Arginine, bypassing intestinal and hepatic arginase degradation. For sports performance and pump: citrulline (6–8g) or citrulline malate 2:1 is now the preferred NO precursor. L-Arginine direct remains preferred in clinical nutrition, wound healing, and erectile function (pycnogenol combination evidence base).
The VINTAGE MI trial (JAMA 2006) found significantly increased 6-month mortality in post-myocardial infarction patients taking L-Arginine 9g/day vs placebo. L-Arginine supplementation is contraindicated for ≥6 months post-MI. This safety signal does not apply to healthy adults or other cardiovascular conditions (hypertension, endothelial dysfunction). Also: HSV reactivation risk at >6g/day in HSV-positive individuals.